<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563809</url>
  </required_header>
  <id_info>
    <org_study_id>0711-E-39-EB</org_study_id>
    <nct_id>NCT01563809</nct_id>
  </id_info>
  <brief_title>Basal Androgens and LH Needing for Ovarian Stimulation for in Vitro Fertilization</brief_title>
  <official_title>The Relationship Between Basal Androgen Levels and the Needing of LH for Controlled Ovarian Stimulation for in Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basing the investigators study on the evidence that basal serum androgens decrease with age,
      the investigators hypothesize that women with serum androgens below a certain level could be
      the population obtaining a benefit of Luteinizing Hormone (LH) supplementation. The objective
      of the present study is to explore the relationship between basal serum androgen levels and
      the need of LH for Controlled Ovarian Stimulation (COS) in IVF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Single centre, open label, randomized controlled trial.

        -  Population: Patients with indication of In Vitro Fertilization (IVF) with the following
           criteria:

        -  Protocol: All patients are tested on day 3-5 of cycle for total Testosterone (Te),
           Dehydroepiandrosetnodione sulphate (DHEAS) and Androstenodione (Δ4). Samples are frozen
           and stored at -20ºC for later analysis. FSH, LH, E2, PRL and TSH are also determined.
           All patients follow Controlled Ovarian Stimulation for IVF with a GnRH agonist long
           protocol. They are randomized to receive recombinant (r) FSH alone (225 IU/day) or r-FSH
           + r-LH (225+75 IU/day).

        -  Sample size calculation: To detect a difference from 40 to 60% (Relative risk: 1.50) on
           pregnancy rate (PR) between patients with low and high androgen levels with respect to
           the mean of each COS protocol, with a confidence level of 95% (error α=0.05) and 80% of
           power (error β=0.2), 97 patients per arm were needed. (n=388 patients). Rounding up, 400
           patients are to be recruited.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>45 days</time_frame>
    <description>Use of rec LH supplementation for controlled ovarian stimulation for IVF</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Low androgens FSH+LH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with androgens below threshold receiving FSH+LH for ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High androgens FSH+LH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with androgens above threshold receiving FSH+LH for ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High androgens FSH alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low androgens, FSH alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH+LH</intervention_name>
    <description>75 IU of LH will be given from stimulation day 1</description>
    <arm_group_label>Low androgens FSH+LH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH+LH</intervention_name>
    <description>75 IU of LH will be given from stimulation day 1</description>
    <arm_group_label>High androgens FSH+LH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1st-2nd IVF cycle

          -  Regular cycle (25-35 days)

          -  Age 18 - 42

          -  BMI: 18-29.9

        Exclusion Criteria:

          -  LH:FSH &gt; 2

          -  Low response background (&lt; 5 oocytes)

          -  Recurrent pregnancy loss

          -  Preimplantational genetic diagnosis indication

          -  Any systemic, metabolic or endocrinological disorder.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI VALENCIA</investigator_affiliation>
    <investigator_full_name>Ernesto Bosch</investigator_full_name>
    <investigator_title>Medical Director IVI Valencia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

